Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProPhase LabsPRPH +1.03% EV-to-OCF is -1.70 as of Jul. 25, 2026. The stock has 5 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, ProPhase Labs ranks better than 60.28% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, ProPhase Labs's Enterprise Value is $9.70 Mil.
ProPhase Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.71 Mil. Therefore, ProPhase Labs's EV-to-OCF for today is -1.70.
The historical rank and industry rank for ProPhase Labs's EV-to-OCF or its related term are showing as below:
PRPH'
s EV-to-OCF Range Over the Past 10 Years
Min: -78.94 Med: -5.75 Max: 32.32
Current: -1.7
During the past 13 years, the highest EV-to-OCF of ProPhase Labs was 32.32. The lowest was -78.94. And the median was -5.75.
PRPH's EV-to-OCF is ranked better than 60.28% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.085
vs PRPH: -1.70
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ProPhase Labs's PE Ratio (TTM) for today is calculated as:
ProPhase Labs's share price for today is $0.0586.
ProPhase Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.945.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ProPhase Labs EV-to-OCF Related Terms
ProPhase Labs EV-to-OCF Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, ProPhase Labs's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's EV-to-OCF falls into.
ProPhase Labs's current Enterprise Value is $9.70 Mil.
ProPhase Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProPhase Labs (PRPH) has a EV-to-OCF of -1.70 as of Jul. 25, 2026. According to the industry distribution chart, ProPhase Labs ranks #85 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 39.7%.
Is ProPhase Labs' EV-to-OCF too high?
ProPhase Labs' current EV-to-OCF is -1.70. Based on the distribution chart, ProPhase Labs ranks #85 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does ProPhase Labs' EV-to-OCF compare to IDTA and IVRO?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #85 out of 214 companies for EV-to-OCF. This puts ProPhase Labs in the upper half of its industry. The industry median EV-to-OCF is 6.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.09, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current EV-to-OCF is -1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.91, compared to a current price of $0.06 — trading 93.6% below its estimated fair value. The current EV-to-OCF is -1.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current EV-to-OCF is -1.70 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 
